Clinical Trials Browser

Phase 2 × Docetaxel × Head & Neck × Clear all

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2 Active not recruiting

50 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT05408845 2026-04-03

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06223568 2026-03-27

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT03360890 2026-03-13

iPRIME

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Phase 2 Active not recruiting

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT01932697 2026-02-10

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

Phase 2 Completed

81 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT07214987 2026-01-30

PDT For Induction Therapy For Head And Neck Cancer

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07354984 2026-01-21

PIONEER-HN

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT01927744 2025-11-26

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Phase 2 Completed

55 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT05541016 2025-11-04

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Phase 2 Recruiting

Carcinoma, Oropharyngeal Neoplasms

NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Phase 2 Completed

26 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Phase 2 Terminated

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT05252429 2025-09-12

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

Head and Neck Neoplasms

NCT04356170 2025-09-02

TPFmORL

Phase 2 Completed

Head and Neck Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT00665392 2025-08-01

ECHO-07

Phase 2 Completed

42 enrolled 24 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT06940180 2025-06-26

Toripalimab With Chemotherapy for Sinus Cancer

Phase 2 Recruiting

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Paranasal Sinus Neoplasms

NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06895369 2025-03-26

The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Phase 2 Not yet recruiting

Nasopharyngeal Neoplasms, Recurrence

NCT00544414 2025-02-19

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Phase 2 Completed

31 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04649476 2025-01-10

NEOPBOSCC

Phase 2 Completed

68 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT06713057 2024-12-03

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Phase 2 Not yet recruiting

Thyroid Neoplasms

NCT00868491 2024-10-18

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

Phase 2 Completed

Head and Neck Neoplasms

NCT06611137 2024-09-26

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Phase 2 Recruiting

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT00720304 2024-08-22

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

43 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02776163 2024-07-30

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

Phase 2 Completed

Head and Neck Neoplasms

NCT01064479 2024-07-16

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

123 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT06360978 2024-04-11

Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer

Phase 2 Not yet recruiting

Head and Neck Neoplasms

NCT03326947 2024-02-20

Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

Phase 2 Recruiting

Head and Neck Neoplasms

NCT01588431 2024-02-14

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Phase 2 Completed

3 enrolled 7 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01437449 2024-01-30

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 2 Completed

27 enrolled 13 charts

Head and Neck Neoplasms

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT03894891 2023-12-20

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Phase 2 Completed

6 enrolled 14 charts

Head and Neck Neoplasms

NCT06107114 2023-11-22

CZCNRHNSCC

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT06130007 2023-11-13

B2023-153

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT04277858 2023-10-23

NECTORS

Phase 2 Recruiting

Oropharyngeal Neoplasms, Tonsillar Neoplasms

NCT01914900 2023-10-19

Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer

Phase 2 Completed

Mouth Neoplasms

NCT02524275 2023-09-08

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Terminated

14 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

NCT06023875 2023-09-05

NCCCNRHNSCC

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Unknown

Hypopharyngeal Neoplasms